RET and lung cancer: Cutaneous adverse events have also been described with treatment-related rashes of all grades developing in 20% and 14.5% of patients with RET-fusion positive nonsmall cell lung cancer and thyroid cancer respectively within clinical trials—though only few with high grade events.3